Covid-19 antibody startup goes public in $309M IPO
August 06, 2021 at 14:33 PM EDT
Just one year after launching with the sole mission of advancing antibodies to both treat and prevent Covid-19, Adagio Therapeutics has hit the Nasdaq, raising $309 million in an IPO.
